Skip to main content

Arrowhead Pharmaceuticals, Inc.

ARWR
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0000879407

In the last 90 days, Arrowhead Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 2 sales; 501 institutions reported holding it in 13F filings for Q2 2026, worth $9.75B in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Arrowhead Pharmaceuticals, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
2 filings
2 insiders, $1.19M in total
Insiders trading
2
Net value
−$1.19M
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Arrowhead Pharmaceuticals, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Arrowhead Pharmaceuticals, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Olukotun Adeoye YDirector31,600Aug 20, 20263
Perry Michael SDirector111,459Aug 20, 20263
Cohen Matthew GregoryDirector11,882Jun 17, 20261
Lu HongboDirector52,012May 14, 20262
Hamilton James CChief Medical Officer226,958Apr 24, 20265
Apel Daniel JosephChief Financial Officer162,905Apr 24, 20262
O'Brien PatrickCOO547,408Jan 8, 20262
Anzalone Christopher RichardChief Executive Officer3,792,739Jan 5, 20265
Ferrari MauroDirector69,053Dec 30, 20253
Waddill William D.Director56,563Dec 23, 20252
Vakiener VictoriaDirector35,723Dec 23, 20252
Ingram Douglas SDirector46,215Dec 18, 20251
Myszkowski Kenneth AllenChief Financial Officer455,433Jan 7, 20250
Given Douglas BDirector124,167Dec 18, 20240
Oliver TracieChief Commercial Officer127,107Jul 3, 20240
San Martin JavierChief Medical Officer198,497Jan 8, 20240
De Backer MarianneDirector31,267Jan 11, 20230

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 20, 2026 (view filing)5:25 PM ETAug 182 daysOlukotun Adeoye YDirectorSSale−2.00K$86.96−$173.9K−6.0%31.6K after
Aug 20, 2026 (view filing)5:22 PM ETAug 182 daysPerry Michael SDirectorSSale−11.6K$87.30−$1.01M−9.4%111.5K after
May 14, 2026 (view filing)May 122 daysLu HongboDirectorSSale−2.97K$76.88−$228.3K−5.4%52.0K after10b5-1
Apr 24, 2026 (view filing)Apr 231 dayHamilton James CChief Medical OfficerSSale−10.0K$75.00−$750.0K−4.2%227.0K after10b5-1
Apr 24, 2026 (view filing)Apr 222 daysApel Daniel JosephChief Financial OfficerSSale−13.1K$71.35−$934.3K−7.4%162.9K after3 lots10b5-1
Mar 9, 2026 (view filing)Mar 54 daysHamilton James CChief Medical OfficerSSale−10.0K$64.19−$641.9K−4.0%237.0K after10b5-1
Jan 5, 2026 (view filing)Jan 5Same dayHamilton James CChief Medical OfficerSSale−40.2K$63.11−$2.53M−18.9%172.0K after7 lots10b5-1
Jan 5, 2026 (view filing)Jan 5Same dayO'Brien PatrickCOOSSale−49.5K$63.11−$3.12M−9.4%474.9K after12 lots10b5-1
Jan 5, 2026 (view filing)Jan 23 daysAnzalone Christopher RichardChief Executive OfficerSSale−13.2K$66.10−$871.7K−0.3%3.79M after2 lots10b5-1
Dec 30, 2025 (view filing)Dec 264 daysFerrari MauroDirectorSSale−7.53K$70.00−$527.1K−9.8%69.1K after10b5-1
Dec 30, 2025 (view filing)Dec 291 dayAnzalone Christopher RichardChief Executive OfficerSSale−51.7K$69.13−$3.58M−1.3%3.81M after2 lots10b5-1
Dec 23, 2025 (view filing)Dec 194 daysVakiener VictoriaDirectorSSale−10.0K$67.68−$679.5K−21.9%35.7K after3 lots10b5-1
Dec 23, 2025 (view filing)Dec 194 daysWaddill William D.DirectorSSale−8.37K$67.65−$566.0K−12.9%56.6K after3 lots10b5-1
Dec 23, 2025 (view filing)Dec 19-224 daysAnzalone Christopher RichardChief Executive OfficerSSale−26.0K$68.04−$1.77M−0.7%3.81M after5 lots10b5-1
Dec 23, 2025 (view filing)Dec 194 daysOlukotun Adeoye YDirectorSSale−10.0K$67.66−$676.6K−22.9%33.6K after3 lots10b5-1
Dec 19, 2025 (view filing)Dec 172 daysAnzalone Christopher RichardChief Executive OfficerSSale−85.0K$64.04−$5.44M−2.2%3.83M after4 lots
Dec 16, 2025 (view filing)Dec 15-161 dayAnzalone Christopher RichardChief Executive OfficerSSale−184.3K$67.00−$12.3M−4.5%3.92M after12 lots
Dec 9, 2025 (view filing)Dec 54 daysPerry Michael SDirectorSSale−16.3K$61.03−$991.7K−12.4%115.2K after
Dec 1, 2025 (view filing)Nov 283 daysFerrari MauroDirectorSSale−8.75K$56.39−$493.4K−11.3%68.8K after
Oct 3, 2025 (view filing)Oct 12 daysHamilton James CChief Medical OfficerSSale−20.0K$35.00−$700.0K−8.6%212.1K after10b5-1
Sep 16, 2025 (view filing)Sep 124 daysHamilton James CChief Medical OfficerSSale−15.0K$30.00−$450.0K−6.1%232.1K after10b5-1
Sep 4, 2025 (view filing)Sep 22 daysHamilton James CChief Medical OfficerSSale−15.0K$25.00−$375.0K−5.7%247.1K after10b5-1
Aug 15, 2025 (view filing)Aug 13-152 daysHamilton James CChief Medical OfficerSSale−10.0K$20.00−$200.0K−3.7%262.1K after2 lots10b5-1
Apr 11, 2025 (view filing)Apr 9-112 daysAnzalone Christopher RichardChief Executive OfficerSSale−141.1K$10.87−$1.53M−3.5%3.92M after5 lots
Mar 17, 2025 (view filing)Mar 134 daysAnzalone Christopher RichardChief Executive OfficerSSale−51.4K$15.07−$775.0K−1.3%4.06M after
Mar 5, 2025 (view filing)Mar 3-42 daysAnzalone Christopher RichardChief Executive OfficerSSale−300.0K$17.58−$5.27M−7.4%3.77M after2 lots10b5-1
Jan 27, 2025 (view filing)Jan 234 daysOlukotun Adeoye YDirectorSSale−959$21.00−$20.1K−2.6%35.8K after10b5-1
Jan 7, 2025 (view filing)Jan 61 dayHamilton James CChief Discovery/Trans MedicineSSale−32.7K$19.82−$648.8K−10.7%272.1K after2 lots10b5-1
Jan 7, 2025 (view filing)Jan 6-71 dayO'Brien PatrickCOO and General CounselSSale−37.2K$19.80−$736.1K−6.6%527.2K after3 lots10b5-1
Jan 7, 2025 (view filing)Jan 6-71 dayMyszkowski Kenneth AllenChief Financial OfficerSSale−45.2K$19.77−$893.1K−9.0%455.4K after4 lots10b5-1
Jan 6, 2025 (view filing)Jan 24 daysAnzalone Christopher RichardChief Executive OfficerSSale−11.5K$19.05−$219.5K−0.3%3.76M after10b5-1
Dec 30, 2024 (view filing)Dec 273 daysOlukotun Adeoye YDirectorSSale−2.85K$20.00−$57.0K−7.2%36.7K after10b5-1
Dec 23, 2024 (view filing)Dec 23Same dayAnzalone Christopher RichardChief Executive OfficerSSale−12.6K$19.59−$246.1K−0.3%3.78M after10b5-1
Dec 20, 2024 (view filing)Dec 182 daysAnzalone Christopher RichardChief Executive OfficerSSale−26.7K$21.24−$567.5K−0.7%3.69M after3 lots10b5-1
Dec 18, 2024 (view filing)Dec 16-172 daysWaddill William D.DirectorSSale−7.50K$21.97−$164.7K−15.7%40.4K after2 lots10b5-1
Dec 18, 2024 (view filing)Dec 16-172 daysGiven Douglas BDirectorSSale−5.55K$21.91−$121.6K−4.3%124.2K after2 lots10b5-1
Dec 18, 2024 (view filing)Dec 162 daysVakiener VictoriaDirectorSSale−8.99K$21.91−$197.1K−29.8%21.2K after10b5-1
Jul 3, 2024 (view filing)Jul 21 dayOliver TracieChief Commercial OfficerSSale−9.39K$25.28−$237.5K−6.9%127.1K after10b5-1
May 6, 2024 (view filing)May 24 daysVakiener VictoriaDirectorSSale−1.80K$23.31−$41.9K−5.6%30.2K after10b5-1
Apr 3, 2024 (view filing)Apr 12 daysHamilton James CChief Discovery/Trans MedicineSSale−6.00K$28.03−$168.2K−2.8%204.9K after
Mar 20, 2024 (view filing)Mar 18-202 daysLu HongboDirectorPPurchase+3.00K$27.66+$83.0K+9.8%33.7K after3 lots
Mar 8, 2024 (view filing)Mar 62 daysMyszkowski Kenneth AllenChief Financial OfficerSSale−40.0K$35.19−$1.41M−9.1%400.6K after
Feb 2, 2024 (view filing)Jan 312 daysAnzalone Christopher RichardChief Executive OfficerSSale−57.5K$32.35−$1.86M−1.5%3.72M after2 lots10b5-1
Jan 17, 2024 (view filing)Jan 125 daysHamilton James CChief Discovery/Trans MedicineSSale−7.94K$36.89−$292.9K−3.6%210.9K after2 lots10b5-1
Jan 16, 2024 (view filing)Jan 115 daysGiven Douglas BDirectorSSale−2.91K$38.06−$110.8K−2.2%129.7K after2 lots10b5-1
Jan 16, 2024 (view filing)Jan 115 daysWaddill William D.DirectorSSale−3.93K$38.07−$149.8K−7.6%47.9K after2 lots10b5-1
Jan 16, 2024 (view filing)Jan 115 daysFerrari MauroDirectorSSale−3.15K$38.06−$119.8K−4.9%60.8K after2 lots10b5-1
Jan 16, 2024 (view filing)Jan 115 daysVakiener VictoriaDirectorSSale−4.72K$38.10−$179.8K−12.9%32.0K after2 lots10b5-1
Jan 8, 2024 (view filing)Jan 53 daysOliver TracieChief Commercial OfficerSSale−74$33.89−$2.51K−0.1%136.5K after10b5-1
Jan 8, 2024 (view filing)Jan 53 daysMyszkowski Kenneth AllenChief Financial OfficerSSale−16.1K$35.27−$567.9K−3.5%440.6K after3 lots10b5-1